|
English
|
正體中文
|
简体中文
|
2831143
|
|
???header.visitor??? :
33124437
???header.onlineuser??? :
842
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"mutimer d"???jsp.browse.items-by-author.description???
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2021-09-04T05:17:01Z |
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
|
Reau N.; Kwo P.Y.; Rhee S.; Brown R.S.; Jr.; Agarwal K.; Angus P.; Gane E.; JIA-HORNG KAO; Mantry P.S.; Mutimer D.; Reddy K.R.; Tran T.T.; Hu Y.B.; Gulati A.; Krishnan P.; Dumas E.O.; Porcalla A.; Shulman N.S.; Liu W.; Samanta S.; Trinh R.; Forns X. |
| 國立成功大學 |
2018 |
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis
|
Puoti, M.;Foster, G.R.;Wang, S.;Mutimer, D.;Gane, E.;Moreno, C.;Chang, T.T.;Lee, S.S.;Marinho, R.;Dufour, J.-F.;Pol, S.;Hezode, C.;Gordon, S.C.;Strasser, Strasser S.I.;Thuluvath, P.J.;Zhang, Zhang Z.;Lovell, S.;Pilot-Matias, T.;Mensa, F.J. |
| 國立成功大學 |
2006-10 |
Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
|
Sollano, J.; De Man, R. A.; Mutimer, D.; Gish, R. G.; Chang, Ting-Tsung; Zhu, J.; Cross, A.; Brett-Smith, H. |
| 國立成功大學 |
2006-07 |
Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
|
De Man, R. A.; Mutimer, D.; Gish, R.; Chang, Ting-Tsung; Zhu, J.; Cross, A.; Brett-Smith, H. |
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
